Access the full text.
Sign up today, get DeepDyve free for 14 days.
N. Otsu (1979)
A Threshold Selection Method from Gray-Level HistogramsIEEE Trans. Syst. Man Cybern., 9
M. Vernejoul (2008)
Sclerosing bone disorders.Best practice & research. Clinical rheumatology, 22 1
Ji Li, I. Sarosi, Xiao-Qiang Yan, S. Morony, C. Capparelli, H. Tan, Susan McCabe, R. Elliott, S. Scully, Gwyneth Van, S. Kaufman, Shao Juan, Yu Sun, J. Tarpley, Laura Martin, Kathleen Christensen, J. Mccabe, P. Kostenuik, H. Hsu, F. Fletcher, C. Dunstan, D. Lacey, W. Boyle (2000)
RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism.Proceedings of the National Academy of Sciences of the United States of America, 97 4
R. Samadfam, Q. Xia, D. Goltzman (2006)
Co‐Treatment of PTH With Osteoprotegerin or Alendronate Increases Its Anabolic Effect on the Skeleton of Oophorectomized MiceJournal of Bone and Mineral Research, 22
J. Guy, M. Shea, M. Shea, C. Peter, R. Morrissey, Wilson Hayes, Wilson Hayes (1993)
Continuous alendronate treatment throughout growth, maturation, and aging in the rat results in increases in bone mass and mechanical propertiesCalcified Tissue International, 53
P. Kostenuik (2005)
Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength.Current opinion in pharmacology, 5 6
A. Ross, T. Bateman, P. Kostenuik, V. Ferguson, D. Lacey, C. Dunstan, S. Simske (2001)
The effects of osteoprotegerin on the mechanical properties of rat boneJournal of Materials Science: Materials in Medicine, 12
S. Morony, K. Warmington, S. Adamu, F. Asuncion, Z. Geng, M. Grisanti, H. Tan, C. Capparelli, C. Starnes, B. Weimann, C. Dunstan, P. Kostenuik (2005)
The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy.Endocrinology, 146 8
J. Ferretti, R. Capozza, N. Mondelo, J. Zanchetta (1993)
Interrelationships between densitometric, geometric, and mechanical properties of rat femora: Inferences concerning mechanical regulation of bone modelingJournal of Bone and Mineral Research, 8
Yu-lin Ma, R. Dai, Z. Sheng, Yan Jin, Yu-hai Zhang, L. Fang, H. Fan, E. Liao (2008)
Quantitative associations between osteocyte density and biomechanics, microcrack and microstructure in OVX rats vertebral trabeculae.Journal of biomechanics, 41 6
洋次郎 一ノ瀬 (2004)
Osteoclastogenesis inhibitory factor/osteoprotegerin reduced bone loss induced by mechanical unloading
M. Whyte, D. Wenkert, Karen Clements, W. Mcalister, S. Mumm (2003)
Bisphosphonate-induced osteopetrosis.The New England journal of medicine, 349 5
T. Ueland, J. Bollerslev, Scott Wilson, Scott Wilson, I. Dick, I. Dick, F.M.A. Islam, F.M.A. Islam, B. Mullin, B. Mullin, Amanda Devine, Amanda Devine, Richard Prince, Richard Prince (2007)
No associations between OPG gene polymorphisms or serum levels and measures of osteoporosis in elderly Australian women.Bone, 40 1
JP Brown, RL Prince, C Deal, RR Recker, DP Kiel, LH de Gregorio, P Hadji, LC Hofbauer, JM Alvaro‐Gracia, H Wang, M Austin, RB Wagman, R Newmark, C Libanati, J San Martin, HG Bone (2009)
Comparison of the effect of denosumab and alendronate on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mass: A randomized, blinded, phase 3 trial, 24
W. Dougall, M. Glaccum, K. Charrier, Kathy Rohrbach, K. Brasel, T. Smedt, E. Daro, Jeffery Smith, Mark Tometsko, C. Maliszewski, A. Armstrong, Victor Shen, S. Bain, D. Cosman, Dirk Anderson, P. Morrissey, J. Peschon, J. Schuh (1999)
RANK is essential for osteoclast and lymph node development.Genes & development, 13 18
B. Abrahamsen, J. Hjelmborg, P. Kostenuik, L. Stilgren, K. Kyvik, S. Adamu, K. Brixen, B. Langdahl (2005)
Circulating amounts of osteoprotegerin and RANK ligand: genetic influence and relationship with BMD assessed in female twins.Bone, 36 4
H. Frost (1987)
Bone “mass” and the “mechanostat”: A proposalThe Anatomical Record, 219
M. Stolina, S. Adamu, M. Ominsky, D. Dwyer, F. Asuncion, Z. Geng, S. Middleton, H. Brown, J. Pretorius, G. Schett, B. Bolon, U. Feige, D. Zack, P. Kostenuik (2005)
RANKL is a Marker and Mediator of Local and Systemic Bone Loss in Two Rat Models of Inflammatory ArthritisJournal of Bone and Mineral Research, 20
N. Udagawa, N. Takahashi, H. Yasuda, A. Mizuno, K. Itoh, Y. Ueno, T. Shinki, M. Gillespie, T. Martin, K. Higashio, T. Suda (2000)
Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function.Endocrinology, 141 9
Charles Capparelli, S. Morony, K. Warmington, S. Adamu, D. Lacey, C. Dunstan, B. Stouch, Steven Martin, P. Kostenuik (2003)
Sustained Antiresorptive Effects After a Single Treatment With Human Recombinant Osteoprotegerin (OPG): A Pharmacodynamic and Pharmacokinetic Analysis in RatsJournal of Bone and Mineral Research, 18
A. Mizuno, Takeshi Kanno, M. Hoshi, Osamu Shibata, K. Yano, N. Fujise, M. Kinosaki, K. Yamaguchi, E. Tsuda, A. Murakami, H. Yasuda, K. Higashio (2002)
Transgenic mice overexpressing soluble osteoclast differentiation factor (sODF) exhibit severe osteoporosisJournal of Bone and Mineral Metabolism, 20
S. Qiu, D. Rao, S. Palnitkar, A. Parfitt (2002)
Age and distance from the surface but not menopause reduce osteocyte density in human cancellous bone.Bone, 31 2
N. Bucay, I. Sarosi, C. Dunstan, S. Morony, J. Tarpley, C. Capparelli, S. Scully, H. Tan, Wei-wei Xu, D. Lacey, W. Boyle, W. Simonet (1998)
osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.Genes & development, 12 9
H. Frost (1960)
In vivo osteocyte death.The Journal of bone and joint surgery. American volume, 42-A
M. Stolina, D. Dwyer, M. Ominsky, T. Corbin, G. Van, B. Bolon, I. Sarosi, J. Mccabe, D. Zack, P. Kostenuik (2007)
Continuous RANKL Inhibition in Osteoprotegerin Transgenic Mice and Rats Suppresses Bone Resorption without Impairing Lymphorganogenesis or Functional Immune Responses1The Journal of Immunology, 179
Ominsky Ominsky, Kostenuik Kostenuik, Cranmer Cranmer, Smith Smith, Atkinson Atkinson (2007)
The RANKL inhibitor OPG‐Fc increases cortical and trabecular bone mass in intact cynomolgus monkeysOsteoporos Int, 18
D. Gatti, F. Antoniazzi, R. Prizzi, V. Braga, M. Rossini, L. Tató, O. Viapiana, S. Adami (2004)
Intravenous Neridronate in Children With Osteogenesis Imperfecta: A Randomized Controlled StudyJournal of Bone and Mineral Research, 20
T. Jämsä, J. Rho, Z. Fan, C. Mackay, S. Marks,, J. Tuukkanen (2002)
Mechanical properties in long bones of rat osteopetrotic mutations.Journal of biomechanics, 35 2
W. Simonet, D. Lacey, C. Dunstan, M. Kelley, Ming-Shi Chang, R. Lüthy, Hung Nguyen, S. Wooden, L. Bennett, T. Boone, G. Shimamoto, M. DeRose, R. Elliott, A. Colombero, H. Tan, Geraldine Trail, J. Sullivan, E. Davy, N. Bucay, L. Renshaw-Gegg, T. Hughes, D. Hill, W. Pattison, P. Campbell, S. Sander, G. Van, J. Tarpley, P. Derby, R. Lee, W. Boyle (1997)
Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone DensityCell, 89
S. Kudlacek, B. Schneider, W. Woloszczuk, P. Pietschmann, R. Willvonseder (2003)
Serum levels of osteoprotegerin increase with age in a healthy adult population.Bone, 32 6
G. Silvestrini, P. Ballanti, M. Sebastiani, M. Leopizzi, M. Vito, E. Bonucci (2008)
OPG and RANKL mRNA and protein expressions in the primary and secondary metaphyseal trabecular bone of PTH-treated rats are independent of that of SOSTJournal of Molecular Histology, 39
M. Ominsky, Xiaodong Li, F. Asuncion, M. Barrero, K. Warmington, D. Dwyer, M. Stolina, Z. Geng, M. Grisanti, H. Tan, T. Corbin, J. Mccabe, W. Simonet, H. Ke, P. Kostenuik (2008)
RANKL Inhibition with Osteoprotegerin Increases Bone Strength by Improving Cortical and Trabecular bone Architecture in Ovariectomized RatsJournal of Bone and Mineral Research, 23
M. Hochberg, S. Greenspan, R. Wasnich, P. Miller, D. Thompson, P. Ross (2002)
Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents.The Journal of clinical endocrinology and metabolism, 87 4
A. Mizuno, N. Amizuka, K. Irie, A. Murakami, N. Fujise, Takeshi Kanno, Yasushi Sato, N. Nakagawa, H. Yasuda, S. Mochizuki, T. Gomibuchi, K. Yano, N. Shima, N. Washida, E. Tsuda, T. Morinaga, K. Higashio, H. Ozawa (1998)
Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin.Biochemical and biophysical research communications, 247 3
V. Shalhoub, J. Faust, W. Boyle, C. Dunstan, M. Kelley, S. Kaufman, S. Scully, G. Van, D. Lacey (1999)
Osteoprotegerin and osteoprotegerin ligand effects on osteoclast formation from human peripheral blood mononuclear cell precursorsJournal of Cellular Biochemistry, 72
A. Rogers, R. Eastell (2005)
Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment.The Journal of clinical endocrinology and metabolism, 90 11
J. Marini (2006)
Should children with osteogenesis imperfecta be treated with bisphosphonates?Nature Clinical Practice Endocrinology &Metabolism, 2
Lei-Sheng Jiang, Zi‐Ming Zhang, Shengdan Jiang, Wei-hua Chen, L. Dai (2007)
Differential Bone Metabolism Between Postmenopausal Women With Osteoarthritis and OsteoporosisJournal of Bone and Mineral Research, 23
Hiroaki Nakamura, T. Tsuji, A. Hirata, Toshio Yamamoto (2002)
Localization of Osteoprotegerin (OPG) on Bone Surfaces and Cement Lines in Rat TibiaJournal of Histochemistry & Cytochemistry, 50
A. Kearns, S. Khosla, P. Kostenuik (2008)
Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.Endocrine reviews, 29 2
D. Walker (1973)
Osteopetrosis cured by temporary parabiosis.Science, 180 4088
T. Bateman, C. Dunstan, V. Ferguson, D. Lacey, R. Ayers, S. Simske (2000)
Osteoprotegerin mitigates tail suspension-induced osteopenia.Bone, 26 5
Akihiro Tomoyasu, M. Goto, N. Fujise, Shinichi Mochizuki, H. Yasuda, T. Morinaga, E. Tsuda, K. Higashio (1998)
Characterization of monomeric and homodimeric forms of osteoclastogenesis inhibitory factor.Biochemical and biophysical research communications, 245 2
M. Stolina, B. Bolon, S. Middleton, D. Dwyer, H. Brown, D. Duryea, Li Zhu, A. Rohner, J. Pretorius, P. Kostenuik, U. Feige, D. Zack (2009)
The Evolving Systemic and Local Biomarker Milieu at Different Stages of Disease Progression in Rat Adjuvant-Induced ArthritisJournal of Clinical Immunology, 29
Harry Kim, Stephanie Morgan-Bagley, P. Kostenuik (2006)
RANKL Inhibition: A Novel Strategy to Decrease Femoral Head Deformity After Ischemic OsteonecrosisJournal of Bone and Mineral Research, 21
T. Ikeda, M. Utsuyama, K. Hirokawa (2001)
Expression Profiles of Receptor Activator of Nuclear Factor κB Ligand, Receptor Activator of Nuclear Factor κB, and Osteoprotegerin Messenger RNA in Aged and Ovariectomized Rat BonesJournal of Bone and Mineral Research, 16
(2006)
Serum OPG levels are correlated positively with bone strength and inversely with bone turnover in mature OPG transgenic rats
K. Ward, C. Cowell, D. Little (2005)
Quantification of metaphyseal modeling in children treated with bisphosphonates.Bone, 36 6
Mei Zhu, Dezhi Tang, Qiuqian Wu, Suyang Hao, Mo Chen, Chao Xie, R. Rosier, Regis O'Keefe, M. Zuscik, Di Chen (2009)
Activation of β‐Catenin Signaling in Articular Chondrocytes Leads to Osteoarthritis‐Like Phenotype in Adult β‐Catenin Conditional Activation MiceJournal of Bone and Mineral Research, 24
AE Kearns, S Khosla, PJ Kostenuik (2008)
OPG and RANKL regulation of bone remodeling in health and disease, 29
S. Morony, K. Warmington, S. Adamu, F. Asuncion, Z. Geng, M. Grisanti, H. Tan, C. Capparelli, C. Starnes, C. Dunstan, P. Kostenuik (2005)
The RANKL Inhibitor Osteoprotegerin (OPG) Causes Greater Suppression of Bone Resorption and Hypercalcemia Compared to Bisphosphonates in Two Models of Humoral Hypercalcemia of Malignancy
M. Franklin, S. Bu, M. Lerner, E. Lancaster, D. Bellmer, D. Marlow, S. Lightfoot, B. Arjmandi, D. Brackett, E. Lucas, B. Smith (2006)
Dried plum prevents bone loss in a male osteoporosis model via IGF-I and the RANK pathway.Bone, 39 6
Y. Kong, H. Yoshida, I. Sarosi, H. Tan, E. Timms, C. Capparelli, S. Morony, A. Oliveira-dos-Santos, G. Van, A. Itié, W. Khoo, A. Wakeham, C. Dunstan, D. Lacey, T. Mak, W. Boyle, J. Penninger (1999)
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesisNature, 397
PJ Kostenuik, C Capparelli, S Morony, S Adamu, G Shimamoto, V Shen, DL Lacey, CR Dunstan (2001)
OPG and PTH‐(1‐34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats, 142
Juha Tuukkanen, A. Koivukangas, Timo Jämsä, K. Sundquist, Carole MacKay, Sandy Marks (2000)
Mineral Density and Bone Strength Are Dissociated in Long Bones of Rat Osteopetrotic MutationsJournal of Bone and Mineral Research, 15
William Rifkin (2006)
Denosumab in postmenopausal women with low bone mineral density.The New England journal of medicine, 354 22
A Rogers, R Eastell (2005)
REVIEW: Circulating osteoprotegerin ligand and receptor activator for nuclear factor κB ligand: Clinical utility in metabolic bone disease assessment, 90
Printed in U.S.A. Copyright © 2001 by The Endocrine Society OPG and PTH-(1–34) Have Additive Effects on Bone Density and Mechanical Strength in Osteopenic Ovariectomized Rats
Q. Jin, J. Cirelli, Chan Park, J. Sugai, M. Taba, P. Kostenuik, W. Giannobile (2007)
RANKL inhibition through osteoprotegerin blocks bone loss in experimental periodontitis.Journal of periodontology, 78 7
M. Ominsky, P. Kostenuik, P. Cranmer, S. Smith, J. Atkinson (2007)
The RANKL inhibitor OPG-Fc increases cortical and trabecular bone mass in young gonad-intact cynomolgus monkeysOsteoporosis International, 18
R. Goswami (1994)
Primer on the metabolic bone diseases and disorders of mineral metabolismThe Indian Journal of Medical Research, 144
RANKL is an essential mediator of bone resorption, and its activity is inhibited by osteoprotegerin (OPG). Transgenic (Tg) rats were engineered to continuously overexpress OPG to study the effects of continuous long‐term RANKL inhibition on bone volume, density, and strength. Lumbar vertebrae, femurs, and blood were obtained from 1‐yr‐old female OPG‐Tg rats (n = 32) and from age‐matched wildtype (WT) controls (n = 23). OPG‐Tg rats had significantly greater serum OPG (up to 260‐fold) and significantly lower serum TRACP5b and osteocalcin compared with WT controls. Vertebral histomorphometry showed significant reductions in osteoclasts and bone turnover parameters in OPG‐Tg rats versus WT controls, and these reductions were associated with significantly greater peak load in vertebrae tested through compression. No apparent differences in bone material properties were observed in OPG‐Tg rat vertebrae, based on their unchanged intrinsic strength parameters and their normal linear relationship between vertebral bone mass and strength. Femurs from OPG‐Tg rats were of normal length but showed mild osteopetrotic changes, including reduced periosteal perimeter (−6%) and an associated reduction in bending strength. Serum OPG levels in WT rats showed no correlations with any measured parameter of bone turnover, mass, or strength, whereas the supraphysiological serum OPG levels in OPG‐Tg rats correlated negatively with bone turnover parameters and positively with vertebral bone mass and strength parameters. In summary, low bone turnover after 1 yr of OPG overexpression in rats was associated with increased vertebral bone mass and proportional increases in bone strength, with no evidence for deleterious effects on vertebral material properties.
Journal of Bone and Mineral Research – Oxford University Press
Published: Dec 4, 2009
Keywords: RANKL; osteoprotegerin; bone quality; bone resorption; bone strength
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.